Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBC

Giuseppe Viale • 15 Sep 2024
ESMO 2024
Breast Cancer Antibodies Trastuzumab deruxtecan
DESTINY-Breast06

Giuseppe Viale, MD, FRCPath, University of Milan, Milan, Italy, discusses updated findings from the Phase III DESTINY-Breast06 trial (NCT04494425) of trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer (mBC), who had previously received endocrine therapy but no chemotherapy. T-DXd significantly improved progression-free survival (PFS) compared to treatment of physician’s choice (TPC), with consistent benefits across HER2-low and HER2-ultralow subgroups. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giuseppe Viale

DESTINY-Breast15: anticipating the impact of HER2-low status
0:40
DESTINY-Breast15: anticipating the impact of HER2-low status
Giuseppe Viale • 15 Sep 2024
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
0:45
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
Giuseppe Viale • 15 Sep 2024

Related Videos

Omitting adjuvant radiotherapy in older patients with early-stage breast cancer
2:12
Omitting adjuvant radiotherapy in older patients with early-stage breast cancer
Lotte Bouwman • 24 Oct 2026
When can endocrine therapy be omitted in early breast cancer?
3:26
When can endocrine therapy be omitted in early breast cancer?
Lotte Bouwman • 24 Oct 2026
How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals